Small molecule · Acts on amyloid beta neuritic plaques · developed by Lantheus Biosciences Ltd., A Lantheus Company
Florbetaben is a radioactive diagnostic agent labeled with fluorine-18 for positron emission tomography (PET) of the brain. It estimates amyloid beta neuritic plaque density in adults with cognitive impairment. It is studied in Alzheimer's disease and in cardiac and light-chain amyloidosis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 24, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05184088 | Phase 3 | Cardiac Amyloidosis | Completed | LNTH |
| NCT01020838 | Phase 3 | Alzheimer Disease | Completed | LNTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AL AmyloidosisAlzheimer DiseaseATTR AmyloidosisCardiac Amyloidosis
Updated Nov 15, 2026. Something wrong or missing? Report it on the LNTH page.
See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LNTH catalysts and pipeline →